Analyses of the skin molecules in patients with severe refractory asthma.

Analyses of the skin molecules in patients with severe refractory asthma. - Analyses of the skin molecules in patients with severe refractory asthma.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000034232

Enrollment

Registered

2018-10-01

Start date

2018-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial asthma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Panelists with severe refractory asthma based on ASTHMA PREVENTION AND MANAGEMENT GUIDELINE 2015. 2.Panelists who are ambulatory patients of Juntendo University hospital. 3.Panelists who are ages 20 and over. 4.Panelists who agree to have their typical daily routines. 5.Panelists who have uncontrollable asthmatic symptoms by conventional therapy, and need administration of benralizumab.

Exclusion criteria

Exclusion criteria: 1.Panelists who have complications such as pneumonitis, infection, and cancer. 2.Panelists who have treated with omarizumab or mepolizumab. 3.Panelists who are regarded as inappropriate in this study.

Design outcomes

Primary

Measure	Time frame
The relationship between skin molecules and therapeutic effects in severe refractory asthma.	—

Secondary

Measure	Time frame
The relationship of the molecules between skin and blood.	—

Countries

Japan

Contacts

Public ContactYuya Uehara

Kao Corporation Biological Science Research

uehara.yuuya@kao.com+81-285-68-7461

Outcome results